# Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Source: https://onco.cc/trials/nct05393713/  
OnCo record `nct05393713` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of IMC-001 run by Mayo Clinic, terminated.

## Summary

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study is a phase 1 interventional study registered as NCT05393713 by Mayo Clinic, with 3 participants enrolled, started 2022-10-17. Conditions recorded: Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma and Recurrent Metastatic Melanoma. Interventions recorded: Anti-PD-L1 Monoclonal Antibody IMC-001 and Punch Biopsy.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05393713
- Phase: 1
- Setting: Phase 1 Study of the Administration of STI-3031 (Anti-PDL1) Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE in Patients With In-Transit Melanoma (Sofusa-2)
- Sponsor: Mayo Clinic
- Enrolled: 3

## Sources

- ClinicalTrials.gov NCT05393713: https://clinicaltrials.gov/study/NCT05393713

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [IMC-001](https://onco.cc/drugs/imc-001/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05393713.json